A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors

Name: A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors
License: Public Domain

Bolt Biotherapeutics, Inc.

ClinicalTrials.gov · Datasets · License: Public Domain

Open Source ↗

her2-positive solid tumors, her2-positive breast cancer, her2-positive colorectal cancer, her2-positive gastroesophageal cancer, her2-positive endometrial cancer

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Record · ID 432892
Retrieved via Conceptio — every document is proof-bundled with source, license, and retrieval metadata.